JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam
Open Access
- 11 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (8) , 4871-4884
Abstract
Risdiplam is a once-daily oral, survival of motor neuron 2 (SMN2) splicing modifier approved for the treatment of spinal muscular atrophy (SMA). JEWELFISH (NCT03032172) investigated the safety, tolerability, pharmacokinetics (PK), and PK/pharmacodynamic (PD) relationship of risdiplam in non-treatment-naïve patients with SMA. JEWELFISH enrolled adult and pediatric patients (N = 174) with confirmed diagnosis of 5q-autosomal recessive SMA who had previously received treatment with nusinersen (n = 76), onasemnogene abeparvovec (n = 14), olesoxime (n = 71), or were enrolled in the MOONFISH study (NCT02240355) of the splicing modifier RG7800 (n = 13). JEWELFISH was an open-label study with all participants scheduled to receive risdiplam. The most common adverse event (AE) was pyrexia (42 patients, 24%) and the most common serious AE (SAE) was pneumonia (5 patients, 3%). The rate of AEs and SAEs decreased by > 50% from the first to the second year of treatment, and there were no treatment-related AEs that led to withdrawal from treatment. An increase in SMN protein in blood was observed following risdiplam treatment and sustained over 24 months of treatment irrespective of previous treatment. Exploratory efficacy assessments of motor function showed an overall stabilization in mean total scores as assessed by the 32-item Motor Function Measure, Hammersmith Functional Motor Scale—Expanded, and Revised Upper Limb Module. The safety profile of risdiplam in JEWELFISH was consistent with previous clinical trials of risdiplam in treatment-naïve patients. Exploratory efficacy outcomes are reported but it should be noted that the main aim of JEWELFISH was to assess safety and PK/PD, and the study was not designed for efficacy analysis. Trial registration: The study was registered (NCT03032172) on ClinicalTrials.gov on January 24, 2017; First patient enrolled: March 3, 2017.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 22 references indexed in Scilit:
- Do we always need to treat patients with spinal muscular atrophy? A personal view and experienceOrphanet Journal of Rare Diseases, 2021
- Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA studyAnnals of Clinical and Translational Neurology, 2020
- Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single CenterNeuropediatrics, 2020
- Spinal muscular atrophy — insights and challenges in the treatment eraNature Reviews Neurology, 2020
- Muscle strength and motor function in adolescents and adults with spinal muscular atrophyNeurology, 2020
- Age and baseline values predict 12 and 24-month functional changes in type 2 SMANeuromuscular Disorders, 2020
- Combination molecular therapies for type 1 spinal muscular atrophyMuscle & Nerve, 2020
- Ambulatory function in spinal muscular atrophy: Age-related patterns of progressionPLOS ONE, 2018
- Prospective cohort study of spinal muscular atrophy types 2 and 3Neurology, 2012
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995